(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property **Organization**

International Bureau





(10) International Publication Number WO 2015/033351 Al

(43) International Publication Date 12 March 2015 (12.03.2015)

(51) International Patent Classification: A01N 25/30 (2006.01) **A01N 43/40** (2006.01) A01N 59/16 (2006.01) **A61K 8/41** (2006.01) A01N 33/12 (2006.01) A61K 8/49 (2006.01) A 01N 33/08 (2006.01) A61Q 5/00 (2006.01) A01N 25/02 (2006.01)

(21) International Application Number:

PCT/IN20 14/000570

(22) International Filing Date:

2 September 2014 (02.09.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 2640/DEL/2013 6 September 2013 (06.09.2013) IN

- (71) Applicant: JUBILANT LIFE SCIENCES LIMITED [IN/IN]; Plot 1A, Sector 16A, Noida-201 301, Uttar Pradesh (IN).
- (72) Inventors: SHARMA, Vineet; c/o Jubilant Life Sciences Limited, C-26, Sector-59, Noida-201 301, Uttar Pradesh (IN). AGARWAL, Ashutosh; c/o Jubilant Life Sciences Limited, C-26, Sector-59, Noida-201 301, Uttar Pradesh (IN).
- Agent: JAIN, Neena; c/o Jubilant Life Sciences Limited, C-26, Sector-59, Noida-201 301, Uttar Pradesh (IN).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

f inventorship (Rule 4.17(iv))

Published:

with international search report (Art. 21(3))



(54) Title: ANTI-DANDRUFF COMPOSITIONS AND HAIR CARE FORMULATIONS CONTAINING ZINC PYRITHIONE AND QUATERNARY AMMONIUM SALT

(57) Abstract: The present invention discloses a stable biocidal composition with enhanced antifungal activity at low concentration of active (s) and a process for preparing the same. The composition comprises: zinc pyrithione, C8-C18 quaternary ammonium salt (preferably cetylpyridinium chloride), water miscible glycol/polyol/glycol ether/lactam, organic amine and/or alkanol amine. The composition can be formulated into: hair care formulations, antidandruff hair care formulations, water based paints, coatings, adhes ives, hard surface cleaners, fabric care compositions, wood products, plastic products and medical products. The biocidal compositions and the resulting formulations are transparent or opaque and are stable at varying pH and humidity conditions.

ANTI-DANDRUFF COMPOSITIONS AND HAIR CARE FORMULATIONS CONTAINING ZINC PYRITHIONE AND QUATERNARY AMMONIUM SALT

Field of Invention

5

10

15

20

25

The present invention relates to a stable, transparent or opaque biocidal compositions comprising zinc pyrithione alone or in combination with a Cg-Cis quaternary ammonium salt, preferably cetylpyridinium chloride. The compositions possess higher bio-availability and enhanced antifungal activity and are capable for being formulated into various personal care and industrial formulations.

Background of the invention

Zinc pyrithione (ZPTO), also known as zinc pyridine-2-thiol -*N*-ox.ide or 0«-[l-hydroxy-2 (*H*) pyridinethionato]-zinc is a broad spectrum antimicrobial agent and has been used as fungicide and bactericide in various personal care and pharmaceutical products, particularly in antidandruff shampoos. ZPTO is also used as a biologically active agent for cutting oils and coolant systems, as an agent for protecting eel lulosic fibres from loss of tensile strength due to action of fungi and as a preservative for water based paints, coatings, adhesives, wet-state preservatives, hard surface cleaners, fabric care compositions, wood products, plastic products, medical products, fibres or any other application where microorganism growth must be stopped or slowed.

The antifungal and antimicrobial activity of ZPTO depends on the bio-availability of ZPTO molecule on scalp. Because of poor solubility in water (6-12 ppm), the concentration of ZPTO molecules in aqueous media and thereafter on hair and scalp also remains low, leading to poor bio-availability. Also, when used in personal care formulations, it produces white suspension that precipitate in the packaging bottle. Therefore, to overcome these disadvantages of low water solubility, precipitations and poor bio-availability, ZPTO is generally used in excess (1-2% w/w) but higher concentration of ZPTO lacks ready consumer acceptability due to harshness.

There had been many approaches to increase the solubilisation and antimicrobial efficacy of zinc pyrithione.

US 3,636,213 discloses solubilisation of heavy metal pyrithione salts in common organic solvents and/or water by combination with primary alkyl and aryl monoamines or polyalkyleneimines, preferably dodecyl amine and diglycol amine for use in hair dressings. The compositions have pH's from about 8.5-9.0.

US 3,785,985 and US 3,940,482 describe the solubilization of heavy metal pyrithione salts in water and detergent containing compositions with aliphatic polyamine. However, ZPTO solubilized in alcohol/water system using polyethylenimine has pH of about 9.0 or above and reducing pH less than 8.0 leads to precipitation of ZPTO in the system.

5

10

15

20

25

30

US 4,835,149 discloses the use of alkanol and/or alkyl amines in the solublizing a metal pyrithione salt in the preparation of a shampoo effective for the treatment of seborrhea and dandruff. The amines include ethanolamine, diethanolamine, monoisopropylamine and others together with a cosmetically effective amount of an aminopolycarboxylic acid to regulate the pH of the system between 6.5-7.5.

US 6,908,912 discloses a stable, soluble, antimicrobial composition where insoluble metal salts of pyrithione in combination with a zinc source (zinc salts, -oxides, -hydroxides, -borates, -sulfates, -chlorides etc.) were solubilised in an organic amine (1, 2-alkanolamines and 1,3-alkanolamines) alone or in combination with a second organic amine (monomeric and polymeric forms of 1,2-alkyldiamines and 1,3-alkyldiamines). These compositions deliver higher concentration of pyrithione and zinc ions to an application (in-can preservatives and metalworking fluids) and thus provide enhanced biocidal efficacy against microorganisms and bio-films.

It is known that below pH 4.5 zinc complex dissociates into free pyrithione and above pH 9.5, zinc complex hydrolyzes to yield ionized pyrithione and zincate species. Both free and ionized pyrithione are biologically active but being much more water soluble than the zinc complex they are most susceptible to degradation from exposure to light or oxygen. In the patent applications cited above, where different types of amines have been used to solubilize ZPTO, either require pH adjustment, pre-formulation of the actives or give precipitate on pH adjustment. Also these prior arts do not disclose any improved or enhanced antifungal or antimicrobial activity particularly the anti-dandruff efficacy for the resulting solubilized ZPTO as compared to ZPTO suspensions. Further, it is extremely difficult to simultaneously attain superior hair sensory attributes along with higher anti-dandruff efficacy from ZPTO containing compositions (US 2006/0 182696).

WO 20010095717 discloses that cationic polymers can increase the efficacy of zinc pyrithione in an anti-dandruff shampoos by enhancing the deposition and retention of the water insoluble ZPTO particles on scalp. Similarly polyethylenimine or the reaction product of polyethylenimine and ethylene oxide or propylene oxide (US 3,489,686); water-soluble cationic nitrogen-containing polymers or nitrogen-substituted cellulose ether derivatives (US 3,580,853) and piperidinum chloride (US 3,761,417) have also been disclosed to increase the efficacy of ZPTO. However, the effect on adsorption of a metal pyrithione salt such as zinc pyrithione was not found sufficient for required or enhanced anti-dandruff efficacy.

5

10

15

20

30

US 4,557,928 describes the use of acrylamide copolymer quaternium 41 and Methocel to create more efficacious zinc pyrithione anti-dandruff shampoo but these shampoos were found unstable over a long period of time.

Cationic surfactants such as amino or quaternary ammonium hydrophilic moieties has been used as cationic surfactant or emulsifying agent in hair conditioners, shampoos, anti-static formulations, fabric softeners and other cosmetics and toiletries preparations (EP 0034385, EP 0941061, US 2008/0057015, US 8,506,942, US 2012/0064136, US 8,206,694 and US 2012/0100092). Some of them like cetyl pyridinium chloride, is also commonly used as antiseptic and/or antimicrobial component at low concentrations (0.025-0.1%) in many OTC health care products (creams, dentifrices, deodorizing and antiperspirant preparations mouth washes, toothpastes, lozenges, throat sprays, cough syrups, nasal sprays and pre-moistened wipes) deodorant.

US 2007/0020221 describes the use of cetylpyridinium chloride (CPC) as a skin lightening or pigmentation reducing cosmetic agent in cosmetic compositions to regulate the condition of mammalian keratinous tissue particularly for preventing, retarding, and/or treating uneven skin tone.

US 2006/0241 190 describes the specific utility of cetylpyridinium chloride in cosmetic compositions as a keratolytic active with SLES for the treatment of psoriasis, eczema and like skin disorders.

As antimicrobial active in shampoos and/or hair care products, US 201 1/0287074 describes the use of CPC as secondary antimicrobial agent in the form of a micro-emulsion. US 2012/012172 provides an antimicrobial composition with a synergistic effect of laurylamine oxide and CPC. This composition which has strong antimicrobial efficacy can be

incorporated into shampoos for the treatment of fungal and/or bacterial infection on skin or mucosal surfaces.

Although the prior art describes that cationic polymers can enhance the deposition of ZPTO on scalp, it is extremely difficult to formulate their stable composition as they show problems in formulation compatibility particularly with ZPTO, resulting in loss of transparency, drop in viscosity and instability over a long period of time.

5

10

15

20

25

30

Thus, there is a need to develop antimicrobial stock compositions and/or personal care formulations with ZPTO in such a manner that ZPTO remains solubilised, maintains transparency above 90%, remains stable in wide pH range and storage conditions, aesthetically more desirable and simultaneously imparts high anti-dandruff efficacy at low concentration of active(s).

Summary of the Invention

The present invention is directed to transparent or opaque biocidal compositions and their formulations, said composition comprising zinc pyrithione either alone or in combination with a C_8 - C_{18} quaternary ammonium salt, preferably cetylpyridinium chloride.

The compositions of the present invention can be transparent or opaque, possess higher bio-availability and enhanced anti-dandruff efficacy at lower concentration of active(s), are stable at varying pH and humidity conditions and can be easily formulated into various personal care and industrial formulations.

An embodiment of the present invention is directed to a transparent or opaque stable biocidal composition comprising: (i) 0.5-35% w/w of ZPTO, (ii) 0-20% w/w of a C_8-C_{18} quaternary ammonium salt, preferably cetylpyridinium chloride (iii) 0.5-20% w/w organic amines and/or alkanol amine, (iv) 0.5-60% w/w water soluble glycol/polyol/glycol ether/lactam or mixtures thereof, (v) 0-10% w/w of a dispersant and/or a rheology modifier and/or a suspending agent, (vi) 0-60% w/w of water.

Detailed Description of the Invention

The present invention provides a stable biocidal composition with enhanced antifungal activity and efficacy. The present invention also provides a biocidal composition having one or more C_8 - Ci_8 quaternary ammonium salt in addition to zinc pyrithione. The biocidal

compositions of the present invention possess high bio-availability of zinc pyrithione. The compositions of the present invention is opaque or transparent.

The inventors of the present invention have surprisingly found that quaternary ammonium salt, in particular C_8 - $C|_8$ quaternary ammonium salt such as cetylpyridinium chloride (CPC) possess significant *anti-malassezia* or anti-dandruff activity alone and shows enhanced anti-dandruff activity in combination with lower concentrations of ZPTO. The compositions and formulations of the present invention possess superior anti-dandruff efficacy at lower concentrations of active (s), ZPTO and C_8 - C_{18} quaternary ammonium salt. The compositions of the present invention are stable and also impart better sensorial benefits.

5

25

30

10 The invention described herein in detail using the terms defined below unless otherwise specified.

The term "biocidal composition" as used herein refers to a solution, suspension and/or a dispersion comprising zinc pyrithione either alone or in combination with a C_8 - C_{18} quaternary ammonium salt wherein the said composition is capable of inhibiting microbial growth.

15 The term "stock" as used herein refers to a concentrated solution, suspension and/or a dispersion comprising zinc pyrithione either alone or in combination with a quaternary ammonium salt as active.

The term "zinc pyrithione concentrate" refers to an aqueous suspension of zinc pyrithione in an amount from 25-50% w/w.

The term "personal care formulation" as used herein refers to various toiletries and cosmetic preparation used for general health and hygiene and grooming. Examples of personal care formulation includes but are not limited to shower gel, soap, conditioners, body lotion and shampoo, anti-dandruff shampoo, anti-dandruff hair gel, and the like.

The term ${}^{{}^{{}^{{}}}}\mathbf{C}|_{8}$ quaternary ammonium salt" as used herein refers to salts of quaternary ammonium cations with anions. The quaternary ammonium cations are positively charged polyatomic ions in which a central nitrogen atom is attached to same or different four straight chain or branched alkyl group (having from 8-18 carbon atoms) or a pyridine nitrogen attached to $\mathbf{C_8}$ - $\mathbf{C_{18}}$ alkyl group. Examples of \mathbf{Cg} - $\mathbf{Ci_8}$ quaternary ammonium salt includes but are not limited to methyltrioctyl ammonium chloride, cetyltrimethyl ammonium chloride, decyltrimethyl ammonium chloride, didecyldimethyl ammonium chloride, trimethyltetradecyl ammonium bromide; dodecyl(lauryl) pyridinium chloride, tetradecyl(myristyl) pyridinium chloride, hexadecyl(cetyl) pyridinium chloride, methyl- or ethyl- cetylpyridinium chloride

and octadecyl(stearyl) pyridinium chloride; alkylbenzyldimethyl ammonium halides or benzalkonium halides with chain lengths of C_8 - C_{18} , predominantly C_{12} to C_{16} , like cetalkonium chloride, benzethonium chloride, lauralkonium halide and stearalkonium chloride.

The term "surfactant" as used herein refers to substances which lower the surface tension of the medium in which it is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapour and/or at other interfaces. Surfactants have a hydrophobic (water repellent) part and a hydrophilic ('water loving') part. The hydrophobic part consists of an uncharged carbohydrate group that can be straight, branched, cyclic or aromatic. Depending on the nature of the hydrophilic part the surfactants are classified as anionic, cationic, non-ionic, or amphoteric.

The term "anionic surfactant" as used herein refers to those surfactants where the hydrophilic part consists of a negatively charged group like a sulphonate, sulphate or carboxylate the surfactant. Examples of anionic surfactant include but are not limited to sodium, potassium or ammonium salts of long chain sulphates having carbon chain lengths 6-14, preferably sodium lauryl sulfate (SLS), sodium laureth sulfate (SLES), triethylamine lauryl sulfate, triethylamine lauryl sulfate, triethylamine lauryl sulfate, triethanolamine lauryl sulfate, triethanolamine lauryl sulfate, diethanolamine lauryl sulfate, monoethanolamine lauryl sulfate, ammonium lauryl sulfate, ammonium lauryl sulfate, potassium lauryl sulfate, potassium lauryl sarcosinate, sodium lauryl sarcosinate, sodium lauryl sarcosinate, sodium lauryl sulfate, sodium cocoyl sulfate, sodium lauryl sulfate, potassium cocoyl sulfate, sodium lauryl sulfate, monoethanolamine cocoyl sulfate, monoethanolamine lauryl sulfate, sodium tridecyl benzene sulfonate, sodium dodecyl benzene sulfonate, sodium cocoyl isethionate, amino acid derived surfactants and combinations thereof.

15

20

25

30

The term "cationic surfactant" as used herein refers to those surfactants where the hydrophilic part consists of a positively charged group. Examples of cationic surfactant include but are not limited to cetyl pyridinium chloride, stearyl pyridinium chloride, methyl or ethyl cetyl pyridinium chloride, aralkyl ammonium halides such as benzyl triethyl ammonium chloride, benzalkonium chloride, cetalkonium chloride, benzethonium chloride, lauryltrimethyl ammonium halide, cetrimonium halide or cetyltrimethyl ammonium halide,

5

10

15

glycidyltrimethylammonium halide, tallowtriinethyi ammonium chloride, cocotrimethyl ammonium chloride, vitamin B6 hydrochloride, behenyltrimethyl ammonium chloride (BTAC), octyltrimethyl ammonium chloride, octyldimethylbenzyl ammonium chloride, decyldimethylbenzyl ammonium chloride, stearyldimethylbenzyl ammonium chloride, dioctadecyldimethyl ammonium chloride, dioctadecyldimethyl ammonium chloride, dipalmitoylethyldimethyl ammonium chloride and combinations thereof.

The term "non-ionic surfactant" as used herein refers those surfactants where the hydrophilic part is not charged. Examples of non-ionic surfactant include, but are not limited to Lamesoft P065, polyoxyethylene (20) sorbitan monoleate (Tween 80), polyoxyethylene (20) sorbitan monolaurate (Tween 20), ethoxylated sorbitan monolaurate (Crillet 180) and combinations thereof.

The term "amphoteric surfactant" as used herein refers to those surfactants wherein hydrophilic part can be either positively or negatively charges depending on the pH of the solution. They can act as anionic surfactant in an alkaline solution or as cationic surfactant in an acidic solution. Examples of amphoteric surfactant include but are not limited to cocamidopropyl betaine (CAPB) or cocamide DEA and combinations thereof.

The term "surfactant system" as used herein refers to one or more surfactants selected form anionic surfactant, cationic surfactant, non-ionic surfactant, amphoteric surfactants or a combination thereof.

The term "suspending agents", are as used herein refers to insoluble particles dispersed in a 20 vehicle and help to reduce the sedimentation rate of particles in suspension. The term "dispersants" as used herein are substances which facilitate the dispersion of aggregates and improve the kinetic stability of the particles. The term "rheology modifiers" as used herein refers to compounds/polymers which alter the thickness or viscosity of the system. Throughout the specification, these terms have been used interchangeably. Examples of 25 dispersants and/or rheology modifier and/or suspending agent as used herein include but are not limited to sodium and potassium salts of alkyl-aryl sulfonic acids and/or polymerized alkyl-aryl sulfonic acids and/or formaldehyde complexes, synthetic silicates, castor oil based thixotropes and organic thixoptropes, carboxymethylcellulose, organoclays, synthetic clays, 30 polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol, Stepan TAB-2, Stepan SAB-2, Carbopol ETD 2020, Carbopol Aqua SF-1, Carbopol Ultrez 20, Rheocare TTA, Rheocare C Plus, xanthum gum, dehydroxanthan gum like Amaze XT, methyl

hydroxyethylcellulose like Structure Cell 12000 and combinations thereof. Sodium and potassium salts of alkyl-aryl sulfonic acids and/or polymerized alkyl-aryl sulfonic acids and/or formaldehyde complexes is selected from but not limited to Tytan series, Tysperse series, DARVAN Series, DEMOL Series, DAXAD Series, TAMOL Series, HAROL Series, LOMAR Series and the likes; synthetic silicates is selected from but not limited to sodium aluminium silicate, magnesium aluminum silicates and the likes; organoclays such as Claytone, Tixogel and the likes; synthetic clay such as Veegum, Laponite and the likes.

The term "suitable solvent" as used herein refers to cosmetically acceptable water and water miscible solvents such as glycol, polyol, glycol ethers, lactams and the like. Exemplary water miscible glycols/polyol/glycol ethers include but are not limited to propylene glycol, glycerol, sorbitol, PEG 400, polyglycol 500 DME, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, diethylene glycol monoethyl ether, diethylene glycol dimethyl ether (diglyme), triethylene glycol dimethyl ether (triglyme), tetraethylene glycol dimethyl ether (tetraglyme) and combinations thereof; exemplary lactams include but are not limited to 2-pyrrolidone, *N*-methyl pyrrolidone (NMP), polyvinylpyrrolidone (PVP) and combinations thereof.

10

15

20

25

30

In one embodiment, the present invention provides a transparent, stable biocidal composition of zinc pyrithione. The said composition comprises (i) 0.5-35% w/w of ZPTO, (ii) 0.5-20% w/w organic amines and/or alkanol amine, (iii) 0.5-60% w/w water soluble glycol/polyol/glycol ether/lactam or mixtures thereof, (iv) 0-10% w/w of a dispersant and/or a rheology modifier and/or a suspending agent, (v) 0-60% w/w of water.

In another embodiment, the present invention provides a transparent, stable biocidal composition of zinc pyrithione and a C_8 - C_{18} quaternary ammonium salt. The said composition comprises (i) 0.5-35% w/w of ZPTO, (ii) 0.05-20% w/w of a C_8 - C_{18} quaternary ammonium salt, (iii) 0.5-20% w/w organic amines and/or alkanol amine, (iv) 0.5-60% w/w water soluble glycol/polyol/glycol ether/lactams or mixtures thereof, (v) 0-10% w/w of a dispersant and/or a rheology modifier and/or a suspending agent, (vi) 0-60% w/w of water.

In yet another embodiment the present invention provides an opaque, stable biocidal composition of zinc pyrithione and a C_8 - Ci_8 quaternary ammonium salt, preferably cetylpyridinium chloride. The said composition comprises (i) 0.01-10% w/w zinc pyrithione, (ii) 0.01-10% w/w C_8 - C_{18} quaternary ammonium salt, preferably cetylpyridinium chloride, (iv) 0.5-60% w/w water soluble glycol/polyol/glycol ether/lactam or mixtures thereof, (v) 0-

10% w/w of a dispersant and/or a rheology modifier and/or a suspending agent, (vi) 0-60% w/w of water.

The stable biocidal composition of the present invention and the formulations prepared from it, is in the form of a solution, suspension or dispersion. They are present in transparent or opaque form.

5

20

25

In a preferred embodiment the stable biocidal composition and the formulations prepared from the same are in transparent form. The transparent or opaque stable biocidal composition of the present invention as described herein can be incorporated into various personal care or industrial formulation.

In a preferred embodiment, the compositions of the present invention are incorporated into a personal care formulation.

In one embodiment the present invention provides personal care formulation comprising the 0.01% to 20% w/w of the transparent or opaque, stable biocidal composition of the present invention as described herein.

In another embodiment the present invention provides personal care formulation comprising 0.01% to 10% w/w of the transparent or opaque, stable biocidal composition of the present invention as described herein.

In a preferred embodiment the present invention provides a personal care formulation, said formulation comprising (i) 0.01-10% w/w transparent or opaque stable biocidal composition as described hereinabove, (ii) 5-45% w/w surfactant system, (iii) 15-75% water.

In yet another embodiment, the personal care formulation of the present invention further comprises one or more additional component selected from diluents, suspending agents, humectants, pH regulators, preservatives, perfumes, skin active agents and/or scalp modifiers, hair growth and/or hair loss preventive agents, sunscreens, UV absorbers, vitamins and/or herbal/fruit extracts.

In a preferred embodiment, the compositions of the present invention are incorporated into a hair care formulation.

In the most preferred embodiment, the compositions of the present invention are incorporated into an anti-dandruff hair care formulation.

In a yet another embodiment, the present invention provides a process for the preparation of stable biocidal compositions and their formulations, in particular personal care formulation.

In another embodiment, the present invention provides a process for preparing a transparent, stable biocidal composition as described hereinabove, said process comprising:

- (a) adding an organic amine and/or alkanol amine to zinc pyrithione to obtain a mixture,
- (b) adding a water soluble glycol/polyol/glycol ether/lactam or mixtures thereof to the mixture of step (a),

5

15

20

25

- (c) preparing a solution of the C_8 - C_{18} quaternary ammonium salt, when present, in a suitable solvent and mixing it with a solution or suspension of dispersant,
- (d) adding the mixture of step (b) to the homogenous solution of step (c).
- In another embodiment, the present invention provides a process for preparing an opaque, stable biocidal composition as described hereinabove, said process comprising:
 - (a) preparing a solution of C_8 -Ci₈ quaternary ammonium salt, preferably cetylpyridinium chloride in a suitable solvent and mixing it with a solution or suspension of dispersant to obtain a mixture,
 - (b) adding zinc pyrithione concentrate to mixture obtained in step (a),

In yet another embodiment, the present invention provides a process for preparing a personal care formulation, said process comprising:

- (a) preparing an aqueous solution of one or more surfactants,
- (b) adding a dispersant and/or a rheology modifier and/or a suspending agent to the above solution,
 - (c) adding the opaque or transparent ,stable biocidal composition as described hereinabove to the solution obtained in step (b)
 - (d) adding one or more additional component.

The suitable solvent used in the process of the present invention is selected from cosmetically acceptable water, propylene glycol, glycerol, sorbitol, PEG 400, polyglycol 500 DME, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol dimethyl ether (diglyme), triethylene glycol dimethyl ether (triglyme), tetraethylene glycol dimethyl ether (tetraglyme), 2-pyrrolidone, *N*-methyl pyrrolidone (NMP), polyvinylpyrrolidone (PVP) and combinations thereof.

In a preferred embodiment, the present invention provides a stable biocidal composition and/or personal care formulation wherein zinc pyrithione is present in an amount of 0.5% to 20% w/w.

In a preferred embodiment, the C_8 - C_{18} quaternary ammonium salt is selected from methyltrioctyl ammonium chloride, cetyltrimethyl ammonium bromide, cetylpyridinium chloride, dodecyl(lauryl) pyridinium chloride, tetradecyl(myristyl) pyridinium chloride, hexadecyl(cetyl) pyridinium chloride, methyl- or ethyl- cetylpyridinium chloride and octadecy!(stearyl) pyridinium chloride.

5

15

30

In the most preferred embodiment the C_8 - C_{18} quaternary ammonium salt is cetylpyridinium chloride. The cetylpyridinium chloride is anhydrous or monohydrate.

In a preferred embodiment of the present invention, the C_{8} - C_{18} quaternary ammonium salt is present in an amount of 0.0 1% to 20% w/w.

The organic amines or alkanol amine used in the present invention is selected from the group comprising monoethanol amine (MEA), 3-aminopropyldimethyl amine, 3-methoxypropyl amine, Z>«-(2-hydroxypropyl) amine and combinations thereof; lactam is selected from 2-pyrrolidone, *N*-methyl pyrrolidone (NMP), polyvinylpyrrolidone (PVP) and combinations thereof.

In a preferred embodiment, the organic amines or alkanol amine is selected from one or more of monoethanol amine (MEA), N-methyl pyrrolidone (NMP), polyvinylpyrrolidone (PVP).

The water soluble glycols/polyol/glycol ethers used in the present invention is selected from propylene glycol, glycerol, sorbitol, PEG 400, polyglycol 500 DME, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, diethylene glycol dimethyl ether (diglyme), triethylene glycol dimethyl ether (triglyme), tetraethylene glycol dimethyl ether (tetraglyme) and combinations thereof.

The compositions of the present invention can be transparent or opaque, possess higher bio-availability and anti-dandruff efficacy and at lower concentration of active(s), are stable at varying pH and humidity conditions and can be easily formulated into various personal care and industrial formulations.

The composition of the present invention can be incorporated into various personal care or industrial formulations such as for cutting oils and coolant systems, as an agent for protecting cellulosic fibers from loss of tensile strength due to action of fungi and as a preservative for

water based paints, coatings, adhesives, wet-state preservatives, hard surface cleaners, hair care compositions, fabric care compositions, wood products, plastic products, medical products, fibers or any other antimicrobial application.

EXAMPLES

5 The invention is explained in detail in the following examples which are given solely for the purpose of illustration only and therefore should hot be construed to limit the scope of the invention.

Example 1: Preparation of transparent ZPTO stock:

To the weighed amount of ZPTO (w/w), monoethanolamine was added. Thereafter, NMP was added and contents were stirred with heating at 40-45 °C. Propylene glycol, sorbitol and polyethylene glycol 400 were then added to the above mixture with continuous stirring to obtain the desired transparent composition. An exemplary composition obtained from the above process is tabulated below:

Table 1: Composition of transparent ZPTO stock

Ingredients	15% ZPTO Stock Solution	10% ZPTO Stock Solution
ZPTO	15%	10%
Monoethanol amine	10%	7%
N-methyl pyrrolidone	25%	24%
Propylene glycol	12%	18%
Sorbitol	9.5%	8.5%
PEG 400	10%	12%
Water	18.5%	20.5%

15

20

10

Example 2: Preparation of transparent ZPTO-CPC stock:

ZPTO solution was prepared by dissolving ZPTO in monoethanol amine and NMP with stirring at 40-45 °C. Similarly, CPC solution was prepared by dissolving in propylene glycol. This solution was added to an aqueous solution of dispersant (Tytan N) and sorbitol. To this solution, ZPTO solution was added slowly with continuous stirring to obtain the desired transparent composition. An exemplary composition obtained from the above process is tabulated below:

Table 2: Composition of transparent ZPTO - CPC stock:

Ingredients	Quantity
ZPTO	10%
Monoethanol amine	10%
N-methyl pyrrolidine	25%
CPC	10%
Propylene glycol	25%
Sorbitol	3.5%
Rheocare TTA	1%
Tytan N	0.5%
Water	15%

Example 3: Preparation of opaque ZPTO-CPC stock

5

10

15

20

CPC was dissolved in water in 1:2.5 ratio. A dispersant solution was also prepared. In a separate vessel, Ultrez 20 was sprinkled over the rest of water. After complete wetting (~5 min), contents were stirred at slow speed and then dispersant and CPC compound (10%) solutions were mixed. Mixture was stirred for 15 min at 40°C. Required amount of zinc pyrithione concentrate was added with continuous mixing at high rpm (600). This mixture was stirred for 30 min and finally a stable white suspension was obtained. An exemplary composition obtained from the above process is tabulated below:

Table 3: Composition of opaque stocks suspension of ZPTO and CPC:

Ingredients	Quantity
ZPTO (48% suspension)	10%
CPC	10%
Ultrez 20	1.2%
Water	75%
Tytan N	3.8%

Example 4: Preparation of personal care formulation

In a 250 ml capacity kettle (thick walled beaker), weighed amount of SLES (2EO), SLS (Galaxy 780) and water were taken and heated till 55°C with mixing to make a transparent homogenous mixture. To this hot mixture, weighed amount of suitable rheology modifier (Carbopol Aqua SF-1, Ultrez 20, Rheocare TTA etc.) was added slowly with continuous mixing. To this mixture, required amount of ZPTO solution from the stock solution (as prepared in example 1 or 2), was added drop-wise to obtain a transparent composition[^] The pH of the system was maintained in the range of 6.5-8. Thereafter, CAPB was added at 50°C,

followed by addition of glycerin, hydrovance and aqueous solution of Merquat 3330 (conditioner) below 40°C with continuous stirring. After addition of all above mentioned ingredients, fragrances compatible with aqueous system like Filip ES or Surf ES (Robertet) is added to the system at room temperature (25-30°C). Total weight of kettle was taken and according to water loss, required amount of water was added. The mixture was stirred further for 10-1 5 min and was stored at room temperature in a container.

Table 4: Transparent hair care formulations

Formulation								
Ingredients	1	. 2	3	4	5	6	7	8
Used (in %)								
SLES (2EO-	20.00	22.50	27.00	24.50	30.00	30.50	30.00	28.50
28%)							30.00	28.30
SLS (28%)	8.00	10.00	9.70	10.75	8.75	10.00	11.00	10.00
DI Water	53.00	21.50	24.00	20.25	22.00	18.00	32.00	40.50
Ultrez 20	<u>-</u>			<u> </u>		_	3.25	4.50
Carbopol	6.00	9.00	7.00	_	_	_		
Aqua SF-1	0.00	7.00	7.00		_ ·			
Rheocare TTA	-	-	-	5.25	6.50	8.00	-	-
zinc	_	2.00 (s)	2.00 (s)	2.00 (s)	2.00	2.00	_	_
Pyrithione		2.00 (3)	2.00 (3)	2.00 (3)	(15%)	(10%)		
ZPTO-CPC	_	_		_	_	_	2.00	2.00 .
Mix							(1:1)	(1:1)
Monoethanol	_	12.75	1.00	2.50	_	0.50	_	_
Amine		12.75	1.00	2.30		0.50		
N-methyl		_	8.50	-	4.50	4.00	_	
Pyrrolidone_								
DEGMEE*	-		-	20.50		-	2.25	
NaOH (18%)	0.90	-	<u>-</u>	-	<u>-</u>		_	0.45
CAPB	6.00	5.00	6.00	5.00	8.00	8.00	6.00	8.00
PEG 400	4.00	8.00	5.00	5.00	6.00	6.00	4.50	-
Glycerin	-	-	-	2.00	-	2.50	1	-
PG**	-	-	5.00		2.0	2.25	2.50	2.50
Sorbitol		2.00	2.00		4.00	. •		-
Hydrovance	1.00	1.5	1.50	-	1.00	2.00	2.00	1.55
Merquat Plus 3330	1.10	0.50	1.00	0.50	2.00	1.50	1.00	-
Colaquat CCG	-	-	· -	-	_	-	-	2.00
Neutralizer	-	5.25	0.30	1.75	3.25	4.75	2.50	-
Total formula	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

^{*}DEGMEE = Diethylene glycol monoethyl ether; **PG = Propylene Glycol

5

Example 5: Physical stability studies of the compositions obtained in examples 1-4:

The stability of the compositions and their formulations with time and varying humidity conditions was tested and the results show that the compositions are stable in wide pH range (6.5-12) and show transparency of more than 90%.

5

10

15

Example 6: Antifungal/Anti-dandruff activity studies:

The anti-dandruff efficacy was determined by measuring zone of inhibition using disc diffusion method against *Malassezia furfur* (ATCC No. 14521). In this procedure, 10 μτ of sample was added on the filter paper disc and the disc was kept in the microbial culture swabbed on the culture media. The culture plates were incubated at 37°C for 48 hrs and antifungal activity was evaluated by observing an area of no growth around the disc. An area of no growth around the swatch is known as a zone of inhibition. The results are depicted in Table 5. Similarly, the anti-dandruff activities for ZPTO and ZPTO-CPC stock compositions and shampoo formulations against *M. furfur* have been done and data are summarized below in table 6:

Table 5: Anti-dandruff activities for various ZPTO containing samples against M. Furfur

Example	Sample details	Quantity tested	Anti-dandruff (<i>M.</i> furfur) activity
		(in %)	Zone of Inhibition
			(in mm)
1	ZPTO suspension in water	2%	20 mm
	ZPTO suspension in water	0.2%	20 mm
	ZPTO solution in MEA + NMP	2%	25 mm
	ZPTO solution	0.2%	25 mm
	ZPTO in surfactant + water	2%	20 mm
	ZPTO in surfactant + water	0.2%	20 mm
	ZPTO solution in surfactant+MEA+NMP	2%	25 mm
	ZPTO solution in surfactant+MEA+NMP	0.2%	25 mm
Surfactant -	+ water	2%	No activity
Surfactant -	+ MEA+ NMP+ water		No activity

Table 6: Anti-dandruff activities for stock compositions and shampoo formulations against M.furfur

Example	Sample Details	Quantity tested (%)	Anti-dandruff (M. furfur) activity Zone of Inhibition (in mm)
1	TSP ZPTO Stock (10%)	2%	45
	TSP ZPTO Stock (10%)	1%	42
	TSP ZPTO Stock (10%)	0.5%	42
	TSP ZPTO Shampoo (10%)	0.5%	40
	TSP ZPTO Shampoo (10%)	2%	48
	TSP ZPTO Shampoo (10%)	1%	45
	TSP ZPTO Stock (15%)	2%	48
	TSP ZPTO Shampoo (15%)	2%	45
2	TSP ZPTO-CPC Stock (10-10%)	1-1%	64
	TSP ZPTO-CPC Stock (10-10%)	0.5-0.5%	54
	TSP ZPTO-CPC Shampoo (10-10%)	1-1%	65
	TSP ZPTO-CPC Shampoo (10-10%)	0.5-0.5%	52
- 3	Opaque ZPTO Stock (48%)	2%	30
	Opaque ZPTO Stock (48%)	1%	28
	Opaque ZPTO Stock (48%)	0.5%	20
	Opaque ZPTO Shampoo (2%)	2%	. 25
	Opaque ZPTO Shampoo (2%)	1%	22
	Opaque ZPTO-CPC Stock (10-10%)	1-1%	55
,	Opaque ZPTO-CPC Stock (10-10%)	0.5-0.5%	48
	Opaque ZPTO-CPC Shampoo (10-10%)	1-1%	52
	Opaque ZPTO-CPC Shampoo (10-10%)	0.5-0.5%	46
TSP Sham	poo (Blank)		No Activity
Opaque Sh	nampoo (Blank)		No Activity

^{*}TSP: Transparent

We Claim:

5

15

20

25

- 1. A transparent, stable biocidal composition, said composition comprising:
 - (i) 0.5-35% w/w of zinc pyrithione,
 - (ii) 0-20% w/w of C₈-C₁₈ quaternary ammonium salt,
- (iii) 0.5-20% w/w organic amines and/or alkanol amine,
 - (iv) 0.5-60% w/w water soluble glycol/polyol/glycol ether/lactam or mixtures thereof,
 - (v) 0-10% w/w of a dispersant and/or a rheology modifier and/or a suspending agent,
 - (vi) 0-60% w/w of water.
- 2. A transparent, stable biocidal composition, said composition comprising:
- 10 (i) 0.5-35% w/w of zinc pyrithione,
 - (ii) 0.05-20% w/w of a C_8 - C_{18} quaternary ammonium salt, preferably cetylpyridinium chloride.
 - (iii) 0.5-20% w/w organic amines and/or alkanol amine,
 - (iv) 0.5-60% w/w water soluble glycol/polyol/glycol ether/lactam or mixtures thereof,
 - (v) 0-10% w/w of a dispersant and/or a rheology modifier and/or a suspending agent,
 - (vi) 0-60% w/w of water.
 - 3. An opaque, stable biocidal composition, said composition comprising:
 - (i) 0.01-20% w/w zinc pyrithione,
 - (ii) 0.01-20% w/w C_8 - C_{18} quaternary ammonium salt, preferably cetylpyridinium chloride,
 - (iii) 0.5-60% w/w water soluble glycol/polyol/glycol ether/lactam or mixtures thereof,
 - (iv) 0-10% w/w of a dispersant and/or a rheology modifier and/or a suspending agent,
 - (v) 0-60% w/w of water.
 - **4.** A personal care formulation comprising the transparent or opaque stable biocidal composition as claimed in any one of claims 1, 2 or 3.
 - 5. A personal care formulation, said formulation comprising:
 - (i) 0.01-10% w/w transparent or opaque, stable biocidal composition as claimed in any one of claims 1, 2 or 3,
- 30 (ii) 5-45% w/w surfactant system,
 - (iii) 15-75% water

5

10

25

30

6. The stable biocidal composition as claimed in any one of claims 1 to 3, wherein the C_{8-Ci} guaternary ammonium salt is cetylpyridinium chloride.

- 7. The stable biocidal composition and/or personal care formulation as claimed in any of the claims 1 to 5, wherein the said composition/formulation is in the form of a solution, suspension or dispersion.
- 8. The stable biocidal composition and/or personal care formulation as claimed in claims 1 to 5, wherein zinc pyrithione is present in an amount of 0.5% to 20% w/w.
- 9. The stable biocidal composition and/or personal care formulation as claimed in claims 1 to 5, wherein the C_8 - C_{18} quaternary ammonium salt is present in an amount of 0.01% to 20% w/w.
- 10. The stable biocidal composition and /or personal care formulation as claimed in claims 1 to 5, wherein C₈-C₁₈ quaternary ammonium salt is selected from methyltrioctyl ammonium chloride, cetyltrimethyl ammonium bromide, cetylpyridinium chloride, dodecyl(lauryl) pyridinium chloride, tetradecyl(myristyl) pyridinium chloride, hexadecyl(cetyl) pyridinium chloride, methyl- or ethylcetylpyridinium chloride and octadecyl(stearyl) pyridinium chloride.
 - 11. The stable biocidal composition and /or personal care formulation as claimed in any one of claims 1 to 5, wherein organic amines or alkanol amine is selected form the group comprising monoethanol amine (MEA), 3-aminopropyldimethyl amine, 3-methoxypropyl amine, bw-(2-hydroxypropyl) amine and combinations thereof.
 - 12. The stable biocidal composition and /or personal care formulation as claimed in any one of claims 1 to 5, wherein the water soluble glycols/polyol/glycol ethers are selected from propylene glycol, glycerol, sorbitol, PEG 400, polyglycol 500 DME, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol dimethyl ether (diglyme), triethylene glycol dimethyl ether (tetraglyme) and combinations thereof; lactam is selected from 2-pyrrolidone, *N*-methyl pyrrolidone (NMP), polyvinylpyrrolidone (PVP) and combinations thereof.

13. A personal care formulation as claimed in claim 4 and/or 5, further comprising one or more additional component selected from diluents, suspending agents, humectants, pH regulators, preservatives, perfumes, skin active agents and/or scalp modifiers, hair growth and/or hair loss preventive agents, sunscreens, UV absorbers, vitamins, herbal extracts and the like.

- **14.** A process for preparing a transparent stable biocidal composition as claimed in claim 1 and/or 2, said process comprising:
- (a) adding an organic amine and/or alkanol amine to zinc pyrithione to obtain a mixture,
 - (b) adding a water soluble glycol/polyol/glycol ether/lactam or mixtures thereof to the mixture of step (a),
 - (c) preparing a solution of the C_8 - C_{18} quaternary ammonium salt, when present, in a suitable solvent and mixing it with a solution or suspension of dispersant,
- 15 (d) adding the mixture of step (b) to the homogenous solution of step (c).
 - **15.** A process for preparing an opaque stable biocidal composition as claimed in claim 3, said process comprising:
 - (a) preparing a solution of C_8 - C_{18} quaternary ammonium salt, preferably cetyl-pyridinium chloride in a suitable solvent and mixing it with a solution or suspension of dispersant to obtain a mixture,
 - (b) adding zinc pyrithione concentrate to mixture obtained in step (a).
 - **16.** A process for preparing a personal care formulation comprising:
- 25 (a) preparing an aqueous solution of one or more surfactants,
 - (b) adding dispersant and/or a rheology modifier and/or a suspending agent to the above solution,
 - (c) adding the stable biocidal composition to the solution obtained in step (b)
 - (d) adding one or more additional component.

30

5

10

20

17. The process as claimed in any one of claims 14 or 15, wherein the suitable solvent is selected from cosmetically acceptable water, propylene glycol, glycerol, sorbitol, PEG 400, polyglycol 500 DME, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether, diethylene glycol dimethyl ether

(diglyme), triethylene glycol dimethyl ether (triglyme), tetraethylene glycol dimethyl ether (tetraglyme), 2-pyrrolidone, *N*-methyl pyrrolidone (NMP), polyvinylpyrrolidone (PVP) and combinations thereof.

5 18. The biocidal composition as claimed in claims 1, 2 and/or 3, as and when used in the preparation of hair care formulations, in particular anti-dandruff hair care formulations.

19. The biocidal composition as claimed in claims 1, 2 and /or 3, as and when used as a biologically active agent for cutting oils and coolant systems, as an agent for protecting cellulosic fibers from loss of tensile strength due to action of fungi and as a preservative for water based paints, coatings, adhesives, wet-state preservatives, hard surface cleaners, fabric care compositions, wood products, plastic products, personal care formulations, medical products, fibers or any other antimicrobial application.

15

10

20

25

INTERNATIONAL SEARCH REPORT

International application No PCT/IN2014/000570

A. CLASSIFICATION OF SUBJECT MATTER

INV. A01N43/40

A01N59/16

A01N33/12

A01N33/08

A01N25/02

ADD.

A01N25/30 A61K8/41

A61K8/49

A61Q5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A01N A61K A61Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal , WPI Data, CHEM ABS Data

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	US 4 835 149 A (BURKE JOHN J [US] ET AL) 30 May 1989 (1989-05-30)	1,4-8, 10-14,
Υ	cited in the application column 5; example 5 and 6	17-19 1-19
Х	WO 2013/072163 A2 (HENKEL AG & CO KGAA [DE]) 23 May 2013 (2013-05-23)	4,7-9, 13,18,19
Υ	page 38	1-19
Υ	US 2004/058855 Al (SCHWARTZ JAMES R [US] ET AL) 25 March 2004 (2004-03-25) paragraph [0237]; example 75	4,7-9, 13,18,19 1-19
	-/- ·	

ı	X	Further documents are listed in the	continuation	of Box C.
		i ditirci documento die lioted in tre	CONTINUATION	or box o.

Χ

See patent family annex.

- * Special categories of cited documents :
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" documentwhich may throw doubts on priority claim(s) orwhich is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

4 December 2014

Date of mailing of the international search report

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016 Authorized officer

Sawicki , Marcin

INTERNATIONAL SEARCH REPORT

International application No
PCT/IN2014/000570

C(Continuat	ion). DOCUMENTS CONSIDERED TO BE RELEVANT	,
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	DATABASE MINTEL GNPD [Online]	1-19
	May 2012 (2012-05) , "Dove - Anti -Dandruff condi t i oner" , XP002733293 , Database accessi on no. 1774243 abstract	
X	us 2011/318434 AI (GUTHERY B EUGENE [US]) 29 December 2011 (2011-12-29)	4,7 ,8, 10, 12, 13,19
Υ	paragraph [0074] ; exampl e 2	1-19
X	us 2005/158263 AI (RIOUX MICHELLE L [US] ET AL) 21 July 2005 (2005-07-21)	19
Y	cited in the application paragraphs [0029], [0045], [0144] - [0150]	1-19
Х	us 2003/228272 AI (AMJAD ZAHID [US] ET AL) 11 December 2003 (2003-12-11)	3-5 ,7-9 , 12 , 13 , 18, 19
Υ	paragraph [0079] ; tabl e 1	1-19
Υ	Anonymous: "Bonnoi r Hai r Medi Shampoo", Drugs.com	1-19
	, 27 July 2011 (2011-07-27) , page 2pp, XP002733294, Retri eved from the Internet: URL: http://www.drugs .com/otc/109073/bonnoi r-hai r-medi .html [retri eved on 2014-12-03] page 2	
Y	Wo 97/03637 AI (UNILEVER PLC [GB]; UNILEVER NV [NL]) 6 February 1997 (1997-02-06) page 5, lines 9-14 page 7, line 5 - page 8, line 5	1-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/IN2014/000570

					1 0 1 7 2 1 1	2011/000070
Patent docume		Publication date		Patent family member(s)		Publication date
us 4835149) A	30-05 -1989	CA	1323831	С	02-11-1993
			EP	0268911	A2	01-06-1988
			US	4835149	Α	30-05-1989
wo 2013072		23-05 -2013	DE	102011086635	AI	23-05-2013
W6 2010012	7.2	20 00 2010	WO	2013072163	A2	23-05-2013
				2013072103		25-05-2015
us 2004058	855 AI	25-03 -2004	AU	2003218279	ΑI	03-11-2003
			CA	2481088	ΑI	30-10-2003
			CN	1646124	Α	27-07-2005
			EP	1496899	ΑI	19-01-2005
			HK	1080747	ΑI	15-04-2011
			JР	2005526111	Α	02-09-2005
			MX	PA04009515	Α	26-07-2005
			US	2004058855	ΑI	25-03-2004
			wo	03088965	ΑI	30-10-2003
us 2011318	3434 AI	29-12 -2011	EP	2378872	ΑI	26-10-2011
			US	2011318434	ΑI	29-12-2011
			US	2013289005	ΑI	31-10-2013
			WO	2010080543	Al	15-07-2010
us 2005158	263 AI	21-07 -2005	AU	6054800	Α	31-01-2001
			BR	0011858	Α	02-07-2002
			CA	2375975	ΑI	04-01-2001
			CN	1364056	A	14-08-2002
			EP	1189504	ΑI	27-03-2002
			HK	1048048	ΑI	14-03-2008
			JP	2003522734	A	29-07-2003
			MX	PA01013447		05-12-2002
			US	2004253194	ΑI	16-12-2004
			US	2005158263	Al	21-07-2005
			WO	0100021	Al	04-01-2001
us 200322 8	272 AI	11-12 -2003	NON	IE		
wo 9703637	' Al	06-02 -1997	AR	003457	AI	05-08-1998
			AU	6613596	A	18-02-1997
			BR	9609532	Α	23-02-1999
			CA	2226907	ΑI	06-02-1997
			CN	1195283	A	07-10-1998
			DE	69616330	DI	29-11-2001
			DE	69616330	T2	18-04-2002
			EP	0839022	AI	06-05-1998
			ES	2164905	T3	01-03-2002
				2107000		
				H11509220	Α	17-08-1999
			JP US	H11509220 5723112	A A	17-08-1999 03-03-1998